SARS-CoV-2 variants may seem like a scary new chapter in the pandemic, but coronavirus experts expected their arrival. Scientists in the UNC School of Medicine and Gillings School of Global Public Health are tracking the variants to learn how they differ and affect the world’s chance of ending this pandemic.
For some COVID-19 patients, the initial infection is just the start of the battle. Post-COVID syndrome occurs when a person's symptoms continue long after their infection ends. A new clinic at UNC hopes to not only help these patients, but also provide researchers with valuable data about this strange syndrome.
For decades, scientists warned of the potential for a global coronavirus outbreak. But when SARS-CoV-2 emerged, no therapeutics, drugs, or vaccines were readily available. The Rapidly Emerging Antiviral Drug Development Initiative (READDI) — founded by researchers at UNC and the Structural Genomics Consortium — is not only finding solutions to the COVID-19 pandemic, but also drugs and therapeutics for future viral outbreaks.
Employing wastewater epidemiology — proven useful in outbreaks of polio and opioid use — UNC microbiologist Rachel Noble is leading a state-wide collaboration tracking novel coronavirus outbreaks across North Carolina, gaining insight that testing individuals does not offer. Preliminary results have shown that by using wastewater, researchers can identify COVID-19 hot spots five to seven days before they are reflected by clinical testing results.